Astellas Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Astellas Pharma, Inc.
Keeping Track: Zegalogue Joins Hypoglycemia Space; Keytruda Earns First-Line Esophageal Cancer Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Astellas’ chief medical officer, Bernie Zeiher, shares perspectives on how COVID-19 has forced the health care industry to think differently about patients’ diverse needs and how the best of these changes must become the norm in delivering patient-focused innovations.
The licensing or self-commercialization decision can be important for the success of a biotech company, but do other more fundamental factors concerning the drug dictate a company’s success?
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.
- Other Names / Subsidiaries
- Advanced Cell Technology, Inc.
- Agensys, Inc.
- Audentes Therapeutics, Inc.
- Fujisawa GmbH
- Ganymed Pharmaceuticals AG GmbH
- iota Biosciences
- Mytogen, Inc.
- Nanna Therapeutics Limited
- Perseid Therapeutics LLC
- Potenza Therapeutics Inc.
- Ocata Therapeutics, Inc.
- OSI Pharmaceuticals, LLC (Cell Pathways
- Yamanouchi Pharmaceutical Co., Ltd.
- Ogeda S.A.
- Mitobridge, Inc.
- Mitokyne, Inc.
- Quethera Limited
- Universal Cells, Inc.
- Xyphos Biosciences, Inc.